Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective.
Ee Vien LowHoon Shien TehNicholas Yee Liang HingSuresh Kumar ChidambaramMohan Dass PathmanathanWee-Ric KimWei Jia LeeZhi Wei TehMaheshwara Rao AppannanShahanizan Mohd ZinFaizah Muhamad ZinSamha Bashirah Mohamed AminMastura IsmailAzah Abdul SamadKalaiarasu M PeariasamyPublished in: Drugs - real world outcomes (2024)
In Malaysia, where vaccination rates were high, nirmatrelvir/ritonavir has been shown to be beneficial in the outpatient treatment of adults with COVID-19 who have risk factors; however, it was only marginally cost effective against hospitalization for healthy adults during the Omicron period.